|Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1|
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
|Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas|
JL Teeling, RR French, MS Cragg, J van den Brakel, M Pluyter, H Huang, ...
Blood 104 (6), 1793-1800, 2004
|Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts|
MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ...
Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003
|Mechanisms of killing by anti-CD20 monoclonal antibodies|
MJ Glennie, RR French, MS Cragg, RP Taylor
Molecular immunology 44 (16), 3823-3837, 2007
|Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents|
MS Cragg, MJ Glennie
Blood 103 (7), 2738-2743, 2004
|The biology of CD20 and its potential as a target for mAb therapy|
MS Cragg, CA Walshe, AO Ivanov, MJ Glennie
B cell trophic factors and B cell antagonism in autoimmune disease 8, 140-174, 2005
|Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain|
K Askew, K Li, A Olmos-Alonso, F Garcia-Moreno, Y Liang, P Richardson, ...
Cell reports 18 (2), 391-405, 2017
|Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic|
J Kuroda, H Puthalakath, MS Cragg, PN Kelly, P Bouillet, DCS Huang, ...
Proceedings of the National Academy of Sciences 103 (40), 14907-14912, 2006
|Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics|
MS Cragg, J Kuroda, H Puthalakath, DCS Huang, A Strasser
PLoS medicine 4 (10), e316, 2007
|Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection|
SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ...
Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010
|Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies|
W Alduaij, A Ivanov, J Honeychurch, EJ Cheadle, S Potluri, SH Lim, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4519-4529, 2011
|Anti-CD20 monoclonal antibodies: historical and future perspectives|
SH Lim, SA Beers, RR French, PWM Johnson, MJ Glennie, MS Cragg
haematologica 95 (1), 135, 2010
|CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts|
HTC Chan, D Hughes, RR French, AL Tutt, CA Walshe, JL Teeling, ...
Cancer research 63 (17), 5480-5489, 2003
|CD20 as a target for therapeutic type I and II monoclonal antibodies|
SA Beers, CHT Chan, RR French, MS Cragg, MJ Glennie
Seminars in hematology 47 (2), 107-114, 2010
|Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy|
SH Lim, AT Vaughan, M Ashton-Key, EL Williams, SV Dixon, HTC Chan, ...
Blood, The Journal of the American Society of Hematology 118 (9), 2530-2540, 2011
|Signaling antibodies in cancer therapy|
MS Cragg, RR French, MJ Glennie
Current opinion in immunology 11 (5), 541-547, 1999
|Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics|
MS Cragg, C Harris, A Strasser, CL Scott
Nature Reviews Cancer 9 (5), 321-326, 2009
|Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells|
A Ivanov, SA Beers, CA Walshe, J Honeychurch, W Alduaij, KL Cox, ...
The Journal of clinical investigation 119 (8), 2143-2159, 2009
|Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic|
MS Cragg, ES Jansen, M Cook, C Harris, A Strasser, CL Scott
The Journal of clinical investigation 118 (11), 3651-3659, 2008
|Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation|
SA Beers, CHT Chan, S James, RR French, KE Attfield, CM Brennan, ...
Blood, The Journal of the American Society of Hematology 112 (10), 4170-4177, 2008